Tofacitinib – the fi rst JAK inhibitor in the treatment of ulcerative colitis. Beginning of the therapeutic era of „small molecules“ in infl ammatory bowel disease?

1. Vaníčková R, Lukáš M. „Malé molekuly“ v léčbě idiopatických střevních zánětů. Farmakoterapeutická revue 2018; 4.

2. Cramer JA, Roy A, Burrell A et al. Medication compliance and persistence: terminology and definitions. Value Heal 2008; 11 (1): 44–47. doi: 10.1111/j.1524-4733.2007.00213.x.

3. Šenolt L. Inhibice Janus kinázy v léčbě revmatoidní artritidy. Farmakoterapie 2011 (3): 283–289.

4. Sandborn WJ, Ghosh S, Panes J et al. Tofacitinib, an oral janus kinase inhibitor, in active ulcerative colitis. N Engl J Med 2012; 367 (7): 616–624. doi: 10.1056/NEJMoa1112168.

5. Sandborn WJ, Su C, Sands BE et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2017; 376 (18): 1723–1736. doi: 10.1056/NEJMoa1606910.

6. Rubin DT, Dubinski M, Lukas M et al. Long-term efficacy of tofacitinib in patients who received extended induction therapy: results from OCTAVE open study for tofacitinib delayed responders. J Crohns Colitis 2019; 13 (Suppl 1): S050–S052. doi: 10.1093/ecco-jcc/jjy222.077.

7. European Medicines Agency. Restrictions in use of Xeljanz while EMA reviews risk of blood clots in lungs. 2019. [online]. Available from: https: //www.ema.europa.eu/en/news/restrictions-use-xeljanz-while-ema-reviews-risk-blood-clots-lungs.